Previous 10 | Next 10 |
home / stock / lly / lly articles
The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be res...
Viking Therapeutics Inc (NASDAQ:VKTX) recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 d...
Eli Lilly And Co’s (NYSE:LLY) CEO, David Ricks, shared the pharmaceutical giant’s plans to introduce its obesity drug, tirzepatide...
Higher long-term rates typically matter a lot to equity valuations. However, according to DataTrek, today’s mega-cap stocks are likely to wea...
CNBC’s Jim Cramer has identified three companies that could potentially join the trillion-dollar club, in the wake of Nvidia Corp‘s (NA...
Amgen Inc (NASDAQ:AMGN) is expected to unveil updates on various programs this year, targeting significant markets. Despite concern...
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials ...
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct compreh...
This week, Berkshire Hathaway (NYSE: BRK-A) achieved a historic milestone as its Class A shares closed above $600,000 for the first time. The surge...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...